GB1211
- Generic Name
- GB1211
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C19H16BrF3N4O4S
- CAS Number
- 1978336-95-6
- Unique Ingredient Identifier
- 94EN2E6BLW
- Background
GB1211 is an orally active galectin-3 (Gal-3) inhibitor.
- Associated Conditions
- -
- Associated Therapies
- -
Galecto Reports Third Quarter 2024 Financial Results
Galecto completes strategic review to focus on oncology and severe liver diseases, acquires global rights to BRM-1420 (dual ENL-YEATS and FLT3 inhibitor for AML), appoints Dr. Amy Wechsler to the Board and Matthew Kronmiller as EVP of Strategy and CBO, reports Q3 2024 financial results with a net loss of $3.9 million.
Non-Small Cell Lung Cancer (NSCLC) Clinical Trials 2024: EMA
DelveInsight's 'Non-Small-Cell Lung Cancer Pipeline Insight 2024' covers 135+ companies and 150+ pipeline drugs, highlighting key players like BridgeBio Pharma, Daiichi Sankyo, and Merck. Prominent therapies include Trastuzumab deruxtecan, DS-1062a, and Pembrolizumab. Recent studies by Merck, AstraZeneca, and Gilead focus on Phase 3 trials for V940, Durvalumab, and Zimberelimab, respectively.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath